Malignant hyperthermia in Czechia and Slovakia

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KLINCOVÁ Martina ŠTĚPÁNKOVÁ Dagmar SCHRÖDEROVÁ Ivana KLABUSAYOVÁ Eva OŠŤÁDALOVÁ Edita VALÁŠKOVÁ Iveta FAJKUSOVÁ Lenka ZÍDKOVÁ Jana GAILLYOVÁ Renata ŠTOURAČ Petr

Year of publication 2022
Type Article in Periodical
Magazine / Source British Journal of Anaesthesia
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/abs/pii/S0007091222002422?via%3Dihub
Doi http://dx.doi.org/10.1016/j.bja.2022.04.029
Keywords Malignant hyperthermia; Czechia; Slovakia
Attached files
Description Malignant hyperthermia (MH) is a rare, hereditary, life-threatening pharmacogenetic disorder triggered by some commonly used anaesthetics: all halogenated volatile anaesthetics and the depolarising neuromuscular blocking agent succinylcholine.1 Despite progress in common knowledge, diagnostics, and dantrolene availability, MH is still considered a severe anaesthetic complication. Genes pathogenically connected with MH include RYR1, CACNA1S, and STAC3.2 Prevalence of RYR1 variants associated with MH differs between countries and geographical areas.3 There is one MH diagnostic centre in the Slavic part of Europe located in Brno, Czechia that serves both Czech and Slovak patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info